1stOncology™: Cancer Intelligence Service – Page 59 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

INTERIM REPORT 2026

On September 16, 2026 GenScript reported interim report ended June 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

(Presentation, GenScript, SEP 16, 2026, View Source [SID1234670918])

Theolytics to Showcase its Innovative Oncolytic Immunotherapy Strategy – including THEO-260 in Advanced Ovarian Cancer – at Upcoming Investor and Scientific Events

On September 16, 2026 Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, reported that members of its senior leadership team will participate in a series of upcoming investor, partnering and scientific conferences, as growing clinical and industry interest in oncolytic viruses highlights their potential as a new generation of cancer immunotherapies.

Theolytics will participate in the following events:

LSX Congress USA – September 23-24, 2026, Boston, MA, USA
Presentation: Growth Showcase – September 23 at 2.30 EST
BioCentury Grand Rounds Europe – September 23–25, 2026, Amsterdam, the Netherlands
Presentation: September 23 at 10.20 CET
ESMO Congress – October 23-27, 2026, Madrid, Spain
LSX Inv€$tival Showcase – November 16, 2026, London, UK
Presentation: Biotech Growth stage – November 16 at 10.30 UK
London Life Sciences Week – November 16-20, 2026, London, UK
David Apelian, CEO of Theolytics, said: "Recent clinical and regulatory progress is providing exciting validation of oncolytic viruses as an emerging new class of cancer immunotherapy. At Theolytics, we are building on this momentum by leveraging Adenovo, our proprietary 100,000,000 variant adenoviral library and platform, which is designed to overcome the major barriers that have historically limited the potential of oncolytic viruses, including IV delivery and sustained activity within stroma-rich solid tumours. These upcoming conferences provide an excellent opportunity to discuss the progress of our lead clinical product THEO-260 which is being administered intravenously in ovarian cancer patients in the OCTOPOD IV Study and exhibits 3 unique modes of action; 1) killing of cancer cells, 2) killing of stroma-producing cancer associated fibroblasts (CAFs), and 3) induction of anti-tumour immunity against cancer cells and CAFs."

Growing momentum in oncolytic immunotherapy

Recent advances have renewed interest in the potential of oncolytic viruses to treat cancer, including an important new US product approval and the potential for another oncolytic virus-based therapy to reach the US market in 2027. Alongside direct tumour-cell killing, increasing understanding of oncolytic virus biology has highlighted their potential to remodel the tumour microenvironment, turn immunologically "cold" tumours "hot" and stimulate local and systemic anti-tumour immune responses. This provides opportunities both as monotherapy and in combination with other cancer immunotherapies.

Theolytics is pioneering a differentiated approach to oncolytic immunotherapy, developing targeted adenoviral candidates designed for both direct and intravenous delivery and designed for sustained activity within the challenging microenvironment of stroma-rich tumours. Dense tumour stroma is an important feature of several major and difficult-to-treat cancers, including ovarian, colorectal and pancreatic ductal adenocarcinoma, as well as triple-negative breast cancer.

Theolytics’ lead candidate, THEO-260, is being evaluated in two clinical trials in patients with advanced ovarian cancer: through intravenous (IV) administration in the OCTOPOD-IV study in the UK, Spain and Canada (NCT06618235); and through intraperitoneal (IP) administration in the OCTOPOD-IP study at The University of Texas MD Anderson Cancer Center in the US (NCT07211659).

With funding secured from leading life sciences investors, together with an additional €8 million in non-dilutive funding from Horizon Europe, the European Union’s flagship research and innovation funding programme, Theolytics is well positioned to advance the clinical development of THEO-260 and explore the broader potential of its next-generation oncolytic immunotherapy platform across stroma-rich solid tumours.

(Press release, Theolytics, SEP 16, 2026, View Source [SID1234670914])

Abalos Therapeutics Publishes Two Articles in Viruses Further Validating its AdaptInnate Approach to Treat Solid Tumors

On September 16, 2026 Abalos Therapeutics reported the publication of two peer-reviewed studies in the medical journal Viruses showcasing the anti-tumor and immunostimulatory properties of its proprietary AdaptInnate approach to treating solid tumors. Preclinical mechanistic and in vivo data demonstrate how tumor-adapted mutations in the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) can influence tumor tropism, immune activation and anti-tumor activity. Together, these findings add to the strong scientific rationale supporting Abalos’ AdaptInnate approach, which leverages the unique properties of the non-lytic arenavirus lymphocytic chorimeningitis virus (LCMV) to trigger both adaptive and innate immune responses against the patient’s tumor, including distant metastases. Abalos is currently advancing ABX-001, its first candidate leveraging the AdaptInnate approach, in a Phase 1 study in patients with relapsed or refractory solid tumors.

The publications, entitled "Mutations at Positions 181 and 185 Within the LCMV GP Protein Increase Tumor Cell Infectivity, Limit Induction of Type I Interferon, and Accelerate T Cell Activation" and "Lymphocytic choriomeningitis virus bearing GPC mutations for enhanced tumor tropism and strong anti-tumor activity," characterize the tumor-adapted I181M and R185W glycoprotein (GP) mutations and provide evidence that these naturally occurring adaptations enhance tumor specificity and penetration, promote increased T-cell recruitment and activation, and remodel the tumor microenvironment toward a more immunogenic state. Importantly, in vivo studies demonstrated a favorable safety profile of the mutated virus, where treatment was associated with only minimal adverse effects. Preclinical findings also demonstrated anti-tumor activity across diverse tumor immune landscapes and support the potential for future development in combination with checkpoint inhibition and adoptive T-cell therapy.

"These studies deepen our understanding of how defined modifications to LCMV can increase tumor tropism and activate immune responses, two hallmarks of our AdaptInnate approach. The preferential replication of the virus within tumors following a single systemic administration, coupled with the strong local T-cell responses observed in these studies, validate the on-target mechanism and limited off-tumor exposure," said Jörg Vollmer, Chief Scientific Officer of Abalos Therapeutics. "These insights further reinforce the potential of this approach to generate durable and highly specific anti-tumor immune responses across tumors with diverse immune profiles, helping address key challenges faced by patients with cancers that remain insufficiently responsive to existing immunotherapies."

The new findings corroborate Abalos’ previously published work in Cell Reports Medicine, which characterized the company’s lead candidate ABX-001. Collectively, these studies strengthen the scientific rationale underlying Abalos’ AdaptInnate approach, which uses systemically administered, non-lytic arenaviruses designed to selectively target solid tumors and trigger body-wide durable innate and adaptive immune responses enabled by sustained viral activity in tumor and immune cells without destroying them.

"We are continuing to add important mechanistic evidence supporting our differentiated AdaptInnate approach and its potential to harness the immune-activating properties of arenaviruses to drive targeted and durable immune responses against tumors," said Gerben Moolhuizen, Chief Executive Officer of Abalos Therapeutics. "With initial clinical data for our lead candidate ABX-001 on the horizon, we are on the cusp of bringing a novel drug modality from promising preclinical data to first-in-human evaluation, further defining the therapeutic power of this approach in cancer patients with limited treatment options."

The Phase 1 clinical trial (NCT07231458) is a first-in-human, open-label, multicenter study evaluating the safety, tolerability and preliminary anti-tumor activity of ABX-001 in patients with refractory or relapsed advanced solid tumors. The study’s early efficacy endpoints include overall response rate (ORR), as well as changes in target lesion size. Patient recruitment has been completed, and topline data are expected in 2027.

(Press release, Abalos Therapeutics, SEP 16, 2026, View Source [SID1234670913])

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

On September 16, 2026 NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, reported that Executive Chairman, President and Chief Executive Officer Amir F. Heshmatpour purchased an additional 35,000 shares of NeOnc common stock in the open market on September 15, 2026, for approximately $115,400, at a weighted average price of approximately $3.30 per share, as will be reported in a Form 4 filed with the U.S. Securities and Exchange Commission (SEC).

The purchase follows the Company’s $15 million registered direct offering announced on September 9, 2026, and extends a series of open-market purchases by NeOnc’s senior leadership since the Company reported positive topline Phase 2a results for intranasal NEO100 on August 12, 2026. Since that announcement, Mr. Heshmatpour has purchased 111,000 shares for a total of approximately $418,700, at an average cost of approximately $3.77 per share. Thomas C. Chen, MD, PhD, Founder, Chief Medical Officer and Chief Scientific Officer, has purchased 49,016 shares for approximately $210,000. Together, the two executives have purchased 160,016 shares for approximately $629,000 in the open market, as reflected in Form 4 filings with the SEC, including the Form 4 to be filed for the September 15 purchases.

"The strength of our Phase 2a results reinforces my conviction in NeOnc’s mission and the potential of our NEO platform," said Mr. Heshmatpour. "With my most recent open-market purchases, I have now invested more than $1.5 million of my personal funds in NeOnc shares over the past year. This is a personal investment in our mission, our patients and the long-term value we are working to build alongside our shareholders."

The NEO100-01 Phase 2a study met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047), and median overall survival of 26.09 months. The Company’s second clinical program, NEO212, has completed Phase 1 dose escalation and established a recommended Phase 2 dose.

All purchases were made in the open market using personal funds.

(Press release, Neonc, SEP 16, 2026, View Source [SID1234670912])

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

On September 16, 2026 MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, reported that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation and MAIA has activated 3 sites in the U.S.

MAIA holds FDA Fast Track designation for ateganosine, a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. Prior data from THIO-101 Parts A and B show overall survival (OS) beyond 24 months in eight patients receiving ateganosine sequenced with a checkpoint inhibitor.

"We have worked diligently to advance ateganosine into the U.S. market, and dosing the first patient in the United States represents a major milestone for our ongoing Phase 2 clinical trial," said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. "Our collaborations with some of the nation’s top institutions and foremost oncologists further strengthen the trial as we evaluate ateganosine for patients in advanced stages of this exceedingly hard-to-treat disease. We believe the data generated through the THIO-101 program may also support a potential pathway toward FDA accelerated approval. With patients now enrolled across four continents, the study has evolved into a truly global effort focused on addressing a critical unmet need in cancer care."

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

(Press release, MAIA Biotechnology, SEP 16, 2026, View Source [SID1234670911])